2.73
Schlusskurs vom Vortag:
$2.57
Offen:
$2.61
24-Stunden-Volumen:
629.03K
Relative Volume:
1.02
Marktkapitalisierung:
$280.97M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-8.0294
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
+3.02%
1M Leistung:
-11.65%
6M Leistung:
-28.91%
1J Leistung:
-31.06%
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MXCT
Maxcyte Inc
|
2.73 | 280.97M | 45.44M | -35.43M | -25.39M | -0.34 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-29 | Eingeleitet | Craig Hallum | Buy |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-08-24 | Eingeleitet | BTIG Research | Buy |
2021-08-24 | Eingeleitet | Cowen | Outperform |
2021-08-24 | Eingeleitet | Stephens | Overweight |
2021-08-24 | Eingeleitet | Stifel | Buy |
2021-08-24 | Eingeleitet | Wedbush | Outperform |
2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
Vanguard Group Inc. Sells 345,587 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
Cooley Advises Cell Therapy Biz On London Market Exit - Law360
MaxCyte intends to delist from London's AIM to enhance liquidity - marketscreener.com
MaxCyte to Delist from AIM, Focus on Nasdaq - TipRanks
MaxCyte Announces Change in Voting Rights Structure - TipRanks
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com India
MaxCyte sets date for Q1 2025 financial results reveal By Investing.com - Investing.com South Africa
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
MaxCyte sets date for Q1 2025 financial results reveal - Investing.com
MaxCyte to Announce Q1 2025 Financial Results - TipRanks
Insider Buyers Lose US$201k As MaxCyte Sheds UK£32m - simplywall.st
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
MaxCyte Inc (MXCT) Volatility Hits 6.24% – Here Is What You Should Do - Stocksregister
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com Australia
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges By Investing.com - Investing.com South Africa
MaxCyte Expands Capital with New Stock Issuance - TipRanks
Charles Schwab Investment Management Inc. Decreases Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com
MaxCyte stock plunges to 52-week low, touches $2.75 By Investing.com - Investing.com UK
MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India
MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
Bank of New York Mellon Corp Reduces Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa
MaxCyte executives receive equity incentives - Investing.com India
MaxCyte Awards Stock Options and Units to Executives - TipRanks
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock - Investing.com India
Maxcyte general counsel David Sandoval sells $1,122 in stock - Investing.com
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):